

شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو

# بسم الله الرحمن الرحيم





HANAA ALY



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرونيله



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية التوثيق الإلكترونى والميكروفيلم

## جامعة عين شمس التوثيق الإلكتروني والميكروفيلم قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Ain Shams University
Faculty of Women for Arts Science and Education.

Biochemistry and Nutrition Department

## Comparative Study of Native or Nano Quercetin on Epigenetic modification and Nephropathy Biomarkers post Challenges in Diabetic Hamsters

Thesis

Submitted for Faculty of Women for Arts, Science and Education,
Ain Shams University
In Partial Fulfillment for the Doctor of Philosophy
in Science Degree (PhD) in Biochemistry and Nutrition

#### <u>By</u> Soha Shebl Tawfik Nassar

MSc. in the Biochemistry and Nutrition Department Biochemistry & Nutrition Department, Faculty of Women for Arts, Science and Education, Ain Shams University

#### **Supervisors:**

#### Prof. Dr. Mona Ahmed Sadek

Prof. of Biochemistry and Nutrition,
Biochemistry & Nutrition Department,
Faculty of Women for Arts, Science and Education, Ain Shams University

#### Prof. Dr. Gehan Salah El-Din Moram Aly

Prof. of Nutrition,
Biochemistry & Nutrition Department,
Faculty of Women for Arts, Science and Education, Ain Shams University

#### Dr. Huda Mohammed Ismail

Lecturer of Biochemistry and Nutrition,
Biochemistry & Nutrition Department,
Faculty of Women for Arts, Science and Education, Ain Shams University

## **ACKNOWLEDGEMENT**

First and foremost, thanks to **ALLAH** for most merciful and most gracious who gave me the ability to carry out this work.

Sadek, Prof. of Biochemistry and Nutrition, Biochemistry and Nutrition Department, Faculty of Women for Arts, Science and Education, Ain Shams University, not only for suggesting, planning the point of research and valuable supervision, but also for her great help, guidance, appropriate choice of the research topic, continuous encouragement, she tided me over many difficulties throughout this work. No words seen to be sufficient to describe, to her owe much.

I would like to express heartily thankful to **Prof. Dr. Gehan salah El-Din Moram**, Prof. of Nutrition, Biochemistry and Nutrition Department, Faculty of Women for Arts, Science and Education, Ain Shams University, for helping me, sincere advice, immense guidance and her directions which sat me on the right track as well as supporting me during all steps of this work.

My deep thanks with love to **Dr. Huda Mohamed Ismail**, lecturer of Biochemistry and Nutrition, Biochemistry and Nutrition Department, Faculty of Women for Arts, Science and Education, Ain Shams University, for helping me and valuable advice to me during all steps of this work.

I am thankful to **Prof. Dr. Kawkab Abd El-Aziz**, Prof. of histopathology, Department of Pathology, Faculty of Veterinary Medicine, Cairo University, for the help that she offered in the microscopic examination carried out in this study.

With great pleasure, I would like to express my sincere gratitude to **the staff members** of Biochemistry and Nutrition Department, Faculty of Women for Arts, Science and Education, Ain Shams University, for their encouragement to carry out this work.

Soha Nassar

Diabetic nephropathy (DN) refers to the deterioration of kidney function and is one of the major public health problems, in spite of medical care developing. This disease is multifactorial and their current treatment strategies are only associated with symptomatic relief rather than curbing their progression. Phytochemicals have been consistently proposed as alternative therapy in modern medicine, but their efficacy is somewhat limited by rapid metabolism, insufficient permeability across membranes and decreased its bioavailability and stability in tissues. Fortunately, current advances in nanotechnology present opportunities to overcome such limitations in delivering active phytochemicals candidates.

The main goal of this study was to examine the possible regulatory effects of quercetin nanoparticles (QUNPs) in compare with native quercetin either with or without metformin on DN through different biological, epigenetic, molecular and biochemical measurements in addition of the histopathological changes in kidney tissues sections in DN hamsters. The first phase of this study used high resolution transmission electron microscope (HR-TEM) image to characterize QUNPs and the results revealed that average size of quercetin was in the nanoscale. The biological trial showed that DN hamsters consumed native or nano quercetin with or without metformin caused significant enhancement in nutritional parameters; change in body weight, feed intake, feed efficiency ratio, feed conversion ratio and relative weight of kidney (P < 0.05) as compared to DN untreated group. QUNPs plus metformin treated group was the most effective by virtue of their small size and characteristics, followed by group consumed native quercetin with metformin. Diabetic and nephropathy biomarkers showed a significant improvement in all treated groups as well as increase expression of insulin receptor substrate -1 (IRS-1) and glucose transporter -4 (GLUT-4) genes. Our results illustrated that the effect of QUNPs plus metformin was the most effective in IRS-1 and GLUT-4 gene expression by 618.18% and 253.33%, respectively that correlated with inhibition of histone deacetylase activity (HDACs) by37.52% compared to DN untreated group which in turn improved diabetic and nephropathy biomarkers. Results of gene expression were confirmed by immunohistochemical analysis. Furthermore, antioxidant effects followed the same direction and were apparent through significantly increment in superoxide dismutase and glutathione peroxidase activities. Levels of metabolic dysfunction, inflammation and apoptosis also reflect the treatments on DN. The levels of inflammatory biomarkers decreased in all treated groups, while QUNPs with metformin was the most effective of all tested treatments, where the level of interleukin-6 and tumor necrosis factor-α was decreased by 47.37% 83.75%, respectively compared to DN untreated group. These results were confirmed by histochemical examinations in kidney tissues. Interestingly, all tested treatments significantly exhibit renal improvement; however, QUNPs with metformin was the most effective.

### LIST OF ABBREVIATIONS

| 4-AAP 4- | -aminoantipyrine |
|----------|------------------|
|----------|------------------|

| A/G ratio | Albumin/globulins ratio                     |
|-----------|---|
| AChE      | Acetylcholine esterase                      |
| ACR       | Albumin: creatinine ratio                   |
| AGEs      | Advanced glycation end products             |
| AIDS      | Acquired immunodeficiency syndrome          |
| AIN-93 M  | American Institute of Nutrition-93 for      |
|           | maintenance                                 |
| AKT       | Protein kinase B                            |
| ALEs      | Advanced lipoxidation end products          |
| AMP       | Adenosine monophosphate                     |
| AMPK      | Adenosine monophosphate activated protein   |
|           | kinase                                      |
| AP-1      | Activator protin-1                          |
| aPKC      | Atypical protein kinase C                   |
| AR        | Aldose reductase                            |
| ARIs      | Aldose reductase inhibitors                 |
| ATP       | Adenosine triphosphate                      |
| BCG       | Bromocresol green                           |
| BMP       | Bone-morphogenic protein                    |
| BSA       | Bovin Serum Albumin                         |
| cDNA      | Complementary DNA                           |
| CFTR      | Cystic fibrosis transmembrane conductance   |
|           | regulator                                   |
| CID       | Chemical Industries Development             |
| 3CLpro    | 3-chymotrypsin-like protease                |
| COVID-19  | Corona virus disease -2019                  |
| COX       | Cyclooxygenase                              |
| cPKC      | Conventional protein kinase C               |
| Ct        | Critical threshold                          |
| DAG       | Diacylglycerol                              |
| DHBS      | 3,5-Dichloro-2-hydroxybenzene sulfonic acid |
| DKD       | Diabetic kidney diseases                    |
| DM        | Diabetes mellitus                           |
| DN        | Diabetic nephropathy                        |
| DNA       | Deoxyribonuclic acid                        |
| DPP 4     | Dipeptidyl peptidase 4                      |
| EC        | Endoplasmic cell                            |
| ECM       | Extracellular matrix                        |
| EDTA      | Ethylene diamine tetra acetic acid          |

| Egr1     | Early growth response 1                     |
|----------|---|
| ELISA    | Enzyme-linked immunosorbent assay           |
| EMT      | Epithelial-to- mesenchymal transition       |
| eNOS     | Endothelial nitric oxide synthase           |
| ER       | Endoplasmic reticulum                       |
| ERK      | Extracellular signal-regulated kinases      |
| ESRD     | End-stage renal disease                     |
| FCR      | Feed conversion ratio                       |
| FER      | Feed efficiency ratio                       |
| FFA      | Free fatty acids                            |
| G-6-Pase | Glucose-6-phosphatase                       |
| GBM      | Glomerular basement membrane                |
| GDM      | Gestational diabetes mellitus               |
| GFR      | Glomerular filtration rate                  |
| GLcNAc   | N-acetylglucosamine                         |
| GLP-1    | Glucagon-like peptide 1                     |
| GLUT-4   | Glucose transporter 4                       |
| GO       | Glyoxal                                     |
| GPx      | Glutathione peroxidase enzyme               |
| GR       | Glutathione reductase                       |
| GSH      | Reduced glutathione                         |
| GSSG     | Oxidized Glutathione                        |
| $H_2O_2$ | Hydrogen peroxide                           |
| HAT      | Histone acetyl transferase                  |
| Hb       | Hemoglobin                                  |
| HbA1c    | Glycated hemoglobin                         |
| HDAC     | Histone deacetylase                         |
| HF-HFr   | High fat-High fructose                      |
| HFD      | High- fat diet                              |
| HIV      | Human immunodeficiency viruses              |
| HOMA-IR  | Homeostasis model assessment                |
| HR-TEM   | High Resolution-transmission Electron       |
|          | Microscope                                  |
| HRP      | Horseradish peroxidase                      |
| ICAM-1   | intercellular adhesion molecule-1           |
| IL-6     | Interleukin-6                               |
| iNOS     | Inducible nitric oxide synthase             |
| INS-QT-  | Insulin-quercetin-loaded liquid crystalline |
| LCNPs    | nanoparticles                               |

| IR               | Insulin receptor                            |
|------------------|---|
| IRS-1            | Insulin receptor substrate - 1              |
| LADA             | Latent autoimmune diabetes of adulthood     |
| LSD              | Least significant difference                |
| MAPK             | Mitogen-activated protein kinase            |
| MCP-1            | Monocyte chemoattractant protein-1          |
| MDA              | Malondialdehyde                             |
| MGO              | Methylglyoxal                               |
| MODY             | Maturity- onset diabetes of the young       |
| MRNA             | Messenger ribonucleic acid                  |
| mTOR             | Mammalian target of rapamycin               |
| NaClO            | Sodium hypochlorite                         |
| $NAD^+$          | Nicotinamide adenine dinucleotide           |
| $NADP^{+}$       | Nicotinamide adenine dinucleotide phosphate |
| NADPH            | Reduced nicotinamide adenine dinucleotide   |
|                  | phosphate                                   |
| NBT              | Nitroblue tetrazolium                       |
| NDM              | Neonatal diabetes mellitus                  |
| NEDA             | N-(1-naphthyl)- ethylenediamine             |
| NF-ĸB            | Nuclear factors kappa B                     |
| NO               | Nitric oxide                                |
| NOS3             | Nitric oxide synthase3                      |
| NOX              | NADPH oxidase                               |
| nPKC             | Novel protein kinase C                      |
| NPs              | Nanoparticles                               |
| O <sub>2</sub> - | Superoxide anion                            |
| OD               | Optical denisty                             |
| 8-OHdG           | 8- hydroxydeoxyguanosine                    |
| PAI-1            | Plasminogen activator inhibitor 1           |
| PBMCs            | Peripheral blood mononuclear cells          |
| PBS              | Phosphate buffer saline                     |
| PCR              | Polymerase chain reaction                   |
| Pdx1             | Pancreatic and duodenal homeobox1           |
| PEPCK            | Phosphoenolpyruvate carboxykinase           |
| PFF              | protein free filtrate                       |
| PI3K             | Phosphatidylinositol 3-kinase               |
| PKC              | Protein kinase C                            |
| PLpro            | papain-like protease                        |
| PMS              | Phenazine methosulphate                     |

| PPARγ          | Peroxisome proliferator-activated receptor              |
|----------------|---|
| ΠΑΚγ           | gamma   |
| PTP1B          | protein tyrosine phosphatase 1B                         |
| QUNPs          | Quercetin nanoparticles                                 |
|                | -   |
| RAGEs          | Receptor for advanced glycation end products            |
| RBCs           | Red blood cells   |
| RNA            | Ribonuclic acid   |
| ROS            | Reactive oxygen species                                 |
| rpm            | Round per minute  |
| RT-PCR         | Reserve transcription-polymerase chain reaction         |
| SARS-CoV-2     | Severe acute respiratory syndrome coronavirus -2        |
| SD             | Standard deviation                                      |
| SDH            | Sorbitol dehydrogenase                                  |
| SERCA          | Sarco (endo) plasmic reticulum Ca <sup>2+</sup> -ATPase |
| SGLT 2         | Sodium-glucose co-transporter 2                         |
| SIRTs          | Sirtuins  |
| SOD            | Superoxide dismutase enzyme                             |
| SPSS           | Statistical Package for Social Science                  |
| STAT3          | Signal transducer and activator of transcription 3      |
| STZ            | Streptozotocin  |
| T1DM           | Type 1 diabetes mellitus                                |
| T2DM           | Type 2 diabetes mellitus                                |
| TBA            | Thiobarbituric acid                                     |
| TCA            | Trichloroacetic acid                                    |
| TEM            | Transmission electron microscope                        |
| TGF-β          | Transforming growth factor β                            |
| T <sup>m</sup> | Melting temperature                                     |
| TMB            | Tetra Methyl Benzidine                                  |
| TNF-α          | Tumor necrosis factor-α                                 |
| TRX            | Thioredoxin   |
| TXNIP          | Thioredoxin-interacting protein                         |
| UAE            | Urine albumin excretion                                 |
| UCC            | Urinary creatinine concentration                        |
| UDP            | Uridine diphosphate                                     |
| UV             | Ultraviolet   |
| VEGF           | Vascular endothelial growth factors                     |
| WHO            | World Health Organization                               |
| L              | <u>υ</u>  |

| Subje      | ct   | Page |
|------------|--|------|
|            |  | No.  |
| Abstract   | <del>-</del>   | I    |
|            | bbreviation  | III  |
| List of co |  | VIII |
| List of ta | ables  | XIV  |
| List of fi | gures  | XVI  |
| Introd     |  | 1    |
|            | f the work   | 5    |
|            | v of literature                                      | 7    |
|            | Diabetes mellitus                                    | 7    |
| 1.         | 1.1. Types of diabetes                               | 9    |
|            | 1.2. Etiology of type1 and type 2 diabetes mellitus  | 13   |
|            | 1.3. Complications of diabetes                       | 14   |
| 2.         | Diabetic nephropathy                                 | 17   |
|            | 2.1. Relation between diabetes mellitus and diabetic | 17   |
|            | nephropathy  |      |
|            | 2.2. Risk factor for diabetic nephropathy            | 20   |
|            | 2.3. pathophysiology of diabetic nephropathy         | 20   |
|            | 2.3.1. Hemodynamic changes                           | 20   |
|            | 2.3.2. Structural abnormalities                      | 22   |
|            | 2.3.3. Epigenetic alteration                         | 22   |
|            | 2.3.4. Advanced glycation end-products               | 27   |
|            | 2.3.5. Aldose reductase                              | 29   |
|            | 2.3.6. Oxidative stress as a common mediator         | 32   |
|            | 2.3.7. Protein kinase C                              | 36   |
|            | 2.3.8. Impaired autophagy activity                   | 39   |
|            | 2.4. Prevention and management of diabetic           | 46   |
|            | nephropathy  |      |
|            | 2.4.1. Pharmacological therapy                       | 46   |
|            | 2.4.2. Phytotherapy in management of diabetic        | 48   |
|            | nephropathy  |      |
| 3.         |  | 59   |
|            | 3.1. Health benefits of quercetin                    | 62   |
|            | 3.2. Absorption, metabolism and bioavailability of   | 65   |
|            | quercetin  |      |
| 4.         | Nanoparticles  | 69   |
|            | 4.1. Synthesis of nanoparticles                      | 69   |

| 4.2. Importance of nanoparticles from natural sources in                             | 73         |
|--|------------|
| different diseases   | 75         |
| 4.3. The antidiabetic mechanisms of nanoparticles                                    | 75<br>76   |
| Materials and Methods  | 76         |
| Materials  | 76         |
| 1- Chemicals   | 76         |
| 2- Animals   | 76         |
| 3- Diet  | 76         |
| <i>Methods</i>   | 81         |
| <ol> <li>Synthesis of quercetin nanoparticles</li> </ol>                             | 81         |
| 2. Characterization of quercetin nanoparticles using                                 | 81         |
| High Resolution- Transmission Electron Microscope                                    |            |
| (HR-TEM) technique   |            |
| 3. The acute toxicity study and $LD_{50}$ of quercetin native                        | 82         |
| and nanoparticles  |            |
| 4. Animal trial  | 83         |
| 5. Nutritional evaluations   | 88         |
| 6. Assessment of Nephropathy biomarkers  | 89         |
| 6.1. Assessment of glomerular filtration rate  | 90         |
| 7. Determination of diabetic molecular analysis                                      | 92         |
| 7.1. IRS-1 and GLUT-4 gene expression analysis                                       | 92         |
| 7.2. IRS-1 and GLUT-4 immunohistochemical  | 100        |
| analysis   | 100        |
| 8. Determination of epigenetic modification in diabetic                              | 102        |
| nephropathy  | 100        |
| 8.1. Determination of Histone Deacetylase  | 102        |
| enzyme activity  9. Biochemical Measurements   | 106        |
| 9. Biochemical Measurements 9.1. Evaluation of diabetic biomarkers                   | 106<br>106 |
|  | 106        |
| 9.1.1. Determination of blood glucose concentration                                  | 100        |
| 9.1.2. Determination of serum insulin level  | 107        |
| 9.1.2. Determination of serum insum level 9.1.3. Determination of insulin resistance | 110        |
| 9.1.4. Determination of β- cells function  | 110        |
| 9.1.5. Determination of glycated   | 110        |
| hemoglobin level in blood  | 110        |
| 9.1.6. Determination of serum C- peptide   | 112        |
| 9.2. Evaluation of renal function  | 114        |
| 9.2.1. Determination of serum urea   | 114        |
| concentration  | '          |
| · · · · · · · · · · · · · · · · · · ·  |            |

| 9.2.2. Determination of serum uric acid          | 115 |
|--|-----|
| concentration                                    |     |
| 9.2.3. Determination of serum creatinine         | 117 |
| concentration                                    |     |
| 9.2.4. Determination of serum total protein      | 117 |
| concentration                                    |     |
| 9.2.5. Determination of serum albumin            | 118 |
| concentration                                    |     |
| 9.2.6. Calculation of serum globulins            | 120 |
| 9.2.7. Calculation of A/G ratio                  | 120 |
| 9.2.8. Determination of urine albumin            | 120 |
| concentration                                    |     |
| 9.2.9. Determination of urine creatinine         | 120 |
| concentration                                    | 120 |
| 9.3. Assessment of diabetic nephropathy          | 121 |
| biomarkers in kidney tissues                     |     |
| 9.3.1. Determination of renal advanced           | 121 |
| glycation end products concentration             | 1-1 |
| 9.3.2. Determination of renal 8-                 | 123 |
| hydroxydeoxyguanosine concentration              | 120 |
| 9.3.3. Determination of renal                    | 124 |
| cyclooxygenase-2 activity                        | 12. |
| 9.3.4. Determination of renal aldose             | 125 |
| reductase activity                               | 123 |
| 9.4. Determination of inflammatory and apoptotic | 127 |
| biomarkers                                       | 12, |
| 9.4.1. Determination of serum interleukin-6      | 127 |
| concentration                                    | 127 |
| 9.4.2. Determination of serum tumor              | 128 |
| necrosis factor-α concentration                  | 120 |
| 9.4.3. Determination of DNA fragmentation        | 129 |
| 9.5. Determination of antioxidant biomarkers     | 131 |
| 9.5.1. Determination of renal superoxide         | 131 |
| dismutase enzyme activity                        | 131 |
| 9.5.2. Determination of renal glutathione        | 133 |
| peroxidase enzyme activity                       | 133 |
| 9.6. Assessment of oxidative stress biomarkers   | 136 |
| 9.6.1. Determination of renal                    | 136 |
|  | 150 |
| malondialdehyde concentration                    |     |

| 9.6.2. Determination of renal nitric oxide                      | 137 |
|---|-----|
| concentration   |     |
| 10. Statistical analysis  | 139 |
| 11. Histopathological examination of kidney tissues             | 139 |
| Results and Discussion  | 140 |
| 1. Characterization of quercetin nanoparticles using High       | 140 |
| Resolution- Transmission Electron Microscope technique (HR-TEM) |     |
| 2. Acute toxicity of both of quercetin native and nanoparticles | 143 |
| 3. Oral effects of native or nano quercetin with and without    | 146 |
| metformin on nutritional evaluations of diabetic nephropathy    | 170 |
| hamsters  |     |
| 4. Oral effects of native or nano quercetin with and without    | 153 |
| metformin on nephropathy biomarkers of diabetic                 | 133 |
| nephropathy hamsters  |     |
| 5. Oral effects of native or nano quercetin with and without    | 162 |
| metformin on muscular IRS-1 and GLUT-4 gene expression          | 102 |
| and immunohistochemical measurements of diabetic                |     |
| nephropathy hamsters  |     |
| 6. Oral effects of native or nano quercetin with and without    | 172 |
| metformin on epigenetic modifications of diabetic               |     |
| nephropathy hamsters  |     |
| 7. Oral effects of native or nano quercetin with and without    | 179 |
| metformin on blood diabetic biomarkers of diabetic              |     |
| nephropathy hamsters  |     |
| 8. Oral effects of native or nano quercetin with and without    | 195 |
| metformin on renal function biomarkers of diabetic              |     |
| nephropathy hamsters  |     |
| 9. Oral effects of native or nano quercetin with and without    | 214 |
| metformin on diabetic nephropathy biomarkers in kidney          |     |
| tissues of diabetic nephropathy hamsters                        |     |
| 10.Oral effects of native or nano quercetin with and without    | 227 |
| metformin on serum inflammatory biomarkers and apoptotic        |     |
| changes of diabetic nephropathy hamsters                        |     |
| 11.Oral effects of native or nano quercetin with and without    | 239 |
| metformin on renal tissue antioxidant biomarkers of diabetic    |     |
| nephropathy hamsters  |     |
| 12. Oral effects of native or nano quercetin with and without   | 246 |
| metformin on renal tissue oxidative stress biomarkers of        |     |
| diabetic nephropathy hamsters                                   |     |